Atlas Trials

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Clinical trial NCT04707768 · COMPLETED

Trial details

NCT number
NCT04707768
Sponsor
Akebia Therapeutics
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Anemia Associated With Chronic Kidney Disease (CKD)
Start date
2021-06-18
Primary completion
2023-01-06
Enrollment
456

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.